Metis TechBio (HKG:7666) entered into a global licensing agreement with Boulevard Bio, a U.S.-based biotechnology company under Deerfield Management, for its preclinical trispecific T-cell engager candidate MTS-128, according to a Tuesday Hong Kong bourse filing.
The company will receive an upfront payment of $20 million and is eligible for up to $1.6 billion in development, regulatory and commercial milestone payments, plus tiered royalties on future product sales.
Under the agreement, Boulevard Bio obtained exclusive global rights to develop, manufacture and commercialize MTS-128, a trispecific T-cell engager developed using Metis TechBio's AI-powered NanoForge platform.
Shares of the firm were down nearly 2% in Tuesday afternoon trade.